2019 Clinical Trials DEA History 
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
Veriheal
JUNE 29, 2021
Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 20, 2021
Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. So, given the history and credibility of the Institute, why did BoA terminate the 10-year banking relationship with SRI?
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.
Cannabis Law Report
JULY 9, 2021
Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
Cannabis Law Report
MARCH 21, 2019
Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. Schedule 1 drugs are substances, chemicals, or drugs considered by the federal government to have no medical use and a high potential for abuse such as heroin, LSD, and ecstasy.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. 12, 2019), [link] [ [link] ]. 10, 2019), [link] [ [link] ]. Mitchell et al.,
Expert insights. Personalized for you.
103 
Let's personalize your content